Novel filagrinol-containing emollient

Abstract

Background. In the last decade, there has been a significant increase in interest in the study of the role of epidermal barrier structural integrity in order to determine the prospects for its pathogenetic correction. It is now known that patients with filaggrin gene mutations have increased risk of developing atopic dermatitis, xerosis, ichthyosis, eczema. Filaggrin participates in the formation of a full-fledged stratum corneum, provides formation of a natural moisturizing factor, stabilizing the water balance of the stratum corneum. In Russia, the innovative filaggrin-containing Admera has been registered, which opens up prospects in the management impaired skin barrier function diseases. Aims. Efficacy and safety of "Admera" emollient in patients with primary and secondary xerosis. Materials and methods. A single-center prospective interventional study December 2021 March 2022 at the Department of Skin and Venereal Diseases of the Sechenov University. The study included 32 patients (22 main group, 10 control group) aged 18 to 60 years (29 9.78), 14 men and 18 women diagnosed with atopic dermatitis, skin xerosis. Patients applied moisturizers 3 times a day for 21 days. Performance was evaluated using vIGA-AD, POEM, EASI, 5D Elman scale, SKINDEX-29, HADS, on Capricorn AI, ANTERA 3D machines. Results. A steady regression of clinical symptoms of xerosis was noted during the study by the dynamics of the study scales. The mean EASI score decreased by 67% from 25.25 18.78 screening to 7.8 4.41 control visit (p 0.001). Assessment of POEM index dynamics showed a significant decrease in total score from 18.65 to 6.6 (p 0.001). There was good tolerability of the product and absence of adverse events. Conclusions. The filagrinol-containing emollient Admera (Dr. Reddy's Laboratories Ltd., India) demonstrated high efficacy and safety in all patients. This emollient can be recommended as a basic care product in the treatment schemes and prevention of primary, secondary xerosis, relapses of atopic dermatitis.